A statistical examination of the integration of biotechnology in the Indian pharmaceutical sector Online publication date: Sun, 13-Jul-2003
by Shyama V. Ramani, Claire Putz
International Journal of Biotechnology (IJBT), Vol. 3, No. 3/4, 2001
Abstract: From the beginning of the 1970s a number of Indian pharmaceutical firms had invested in gaining technological competence without having ''formal R&D centres''; and through efficient ''reverse engineering'' had slashed the prices of products otherwise sold by Western multinationals. However, their knowledge base was founded on the chemical technology of creating bulk drugs and during the second half of the 1980s these firms were confronted with biotechnology, a set of techniques that was new and more complex to integrate. Using detailed panel data on a sample of 32 firms active in biopharmaceuticals, this paper attempts to understand the relationships between their size, R&D strategies and market sales. Given the small sample size, the statistical analysis of our data set is limited to the identification of associations between the different variables and is not extended to estimation of models. The methods used are descriptive statistics, principal component analysis and analysis of variance.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook